Mapp Biopharmaceutical Gets Up To $42.3M For Ebola Drug Research

San Diego-based Mapp Biopharmaceuticals is slated to receive up to $42.3M in a bid to accelerate the company's development of a treatment for Ebola, the U.S. Department of Health and Human Services said Tuesday. According to the federal agency, it will provide $24.9M in an 18-month contract with Mapp Biopharmaceutical, with a possible extension of the contract to up to $42.3M. That funding will go towards supporting the government repsonse to the Ebola outbreak in West Africa. Mapp Biopharmaceuticals develops ZMapp, one of the potential treatments for Ebola. The U.S. Department of Health and Human Services said that the grant comes via the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR). Image: cells infected with Ebola, via the National Institute of Health (NIH)..